Newton Health Care Pvt Ltd
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan pharmaceutical manufacturer registered in 2009 with branded-medicine and nutraceutical manufacturing operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Newton Health Care (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 4C, Mezzanine Floor, Badar Commercial Lane No. 6, DHA Phase V Extension, Karachi, Pakistan
- Website
- newtonhc.org ↗
- Phone
- +92 21 37237605
- info@newtonhc.org
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Amixon | Amikacin | 100 mg/2 mL | Injection | 2mlx5's | 092998 | PKR 349.65 | PKR 34.97/mL | 10% below median |
| Amixon | Amikacin | 500 mg/2 mL | Injection | 2mlx5's | 093042 | PKR 986.08 | PKR 98.61/mL | 8% below median |
| Amoebic | Metronidazole | 200 mg/5 mL | Suspension | 120ml | 086591 | PKR 111.00 | PKR 0.93/mL | Near median |
| Azitron | Azithromycin | 500 mg | Tablet | 6's | 086550 | PKR 508.76 | PKR 84.79/tablet | Near median |
| Azitron | Azithromycin | 250 mg | Tablet | 6's | 086559 | PKR 277.51 | PKR 46.25/tablet | Near median |
| Azitron | Azithromycin | 200 mg/5 mL | Suspension | 30ml | 086586 | PKR 569.21 | PKR 18.97/mL | 13% below median |
| Azitron | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 086586 | PKR 305.26 | PKR 20.35/mL | 7% below median |
| Ceftranex | Ceftriaxone | 250 mg | Dry powder for injection | 1's | 092992 | PKR 186.86 | PKR 186.86/vial/unit | 10% below median |
| Ceftranex | Ceftriaxone | 500 mg | Dry powder for injection | 1's | 092993 | PKR 314.50 | PKR 314.50/vial/unit | Near median |
| Ceftranex | Ceftriaxone | 1 g | IV injection | 1's | 092994 | PKR 593.88 | PKR 593.88/vial/unit | Near median |
| Ceftranex | Ceftriaxone | 1.0 g | Dry powder for injection | 1's | 092994 | PKR 593.88 | PKR 593.88/vial/unit | 12% above median |
| Cipton | Ciprofloxacin | 250 mg | Tablet | 10's | 086555 | PKR 240.51 | PKR 24.05/tablet | 5% below median |
| Cipton | Ciprofloxacin | 500 mg | Tablet | 10's | 086556 | PKR 397.76 | PKR 39.78/tablet | 7% below median |
| Cipton | Ciprofloxacin | 750 mg | Tablet | 10's | 086557 | PKR 425.53 | PKR 42.55/tablet | 7% above median |
| Flucaton | Fluconazole | 150 mg | Capsule | 1's | 086580 | PKR 255.31 | PKR 255.31/capsule | Near median |
| Flucaton | Fluconazole | 50 mg/5 mL | Suspension | 35ml | 086585 | PKR 388.51 | PKR 11.10/mL | Near median |
| Luther 20 | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 086564 | PKR 592.03 | PKR 37.00/tablet | 7% below median |
| Luther Dry | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 30ml | 086583 | PKR 166.51 | PKR 5.55/mL | Near median |
| Luther DS 40 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 086565 | PKR 488.42 | PKR 61.05/tablet | Near median |
| Luther Forte 80 | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 086563 | PKR 610.52 | PKR 101.75/tablet | 7% below median |
| Merotenem Injection 1g IVRegistry verified | Meropenem trihydrate eq to meropenem (Blended with Sodium Carbonate) | — | — | — | 116115Official source ↗ | No indexed price | — | — |
| Merotenem Injection 500mg IVRegistry verified | Meropenem Trihydrate Eq. To Meropenem (Blended with Sodium Carbonate) | — | — | — | 116114Official source ↗ | No indexed price | — | — |
| Moxiton | Moxifloxacin | 400 mg | Tablet | 5's | 086551 | PKR 878.78 | PKR 175.76/tablet | Near median |
| NeClari | Clarithromycin | 125 mg/5 mL | Suspension | 60ml | 088182 | PKR 412.57 | PKR 6.88/mL | 7% below median |
| NeClari | Clarithromycin | 250 mg/5 mL | Suspension | 60ml | 088183 | PKR 680.82 | PKR 11.35/mL | 7% below median |
| NeClari | Clarithromycin | 250 mg | Tablet | 10's | 092990 | PKR 444.01 | PKR 44.40/tablet | 7% below median |
| NeClari | Clarithromycin | 500 mg | Tablet | 10's | 092991 | PKR 740.03 | PKR 74.00/tablet | 12% below median |
| Nefotax | Cefotaxime | 250 mg | Dry powder for injection | 1's | 092995 | PKR 105.66 | PKR 105.66/vial/unit | Near median |
| Nefotax | Cefotaxime | 500 mg | Dry powder for injection | 1's | 092996 | PKR 159.25 | PKR 159.25/vial/unit | Near median |
| Nefotax | Cefotaxime | 1 g | Injection | 1's | 092997 | PKR 286.42 | PKR 286.42/vial/unit | Near median |
| Nefotax | Cefotaxime | 1.0 g | Dry powder for injection | 1's | 092997 | PKR 286.42 | PKR 286.42/vial/unit | No comparator |
| Nefspan | Cefixime | 400 mg | Capsule | 5's | 093043 | PKR 564.16 | PKR 112.83/capsule | Near median |
| Nefspan Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 093003 | PKR 314.83 | PKR 10.49/mL | Near median |
| Nefspan Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 093004 | PKR 385.28 | PKR 12.84/mL | Near median |
| Nesunate | Artesunate | 60 mg | Dry powder for injection | 1's | 092999 | PKR 222.01 | PKR 222.01/vial/unit | No comparator |
| Nesunate | Artesunate | 120 mg | Dry powder for injection | 1's | 093000 | PKR 370.00 | PKR 370.00/vial/unit | No comparator |
| Netoplex | Iron polymaltose complex | 50 mg/5 mL | Syrup | 120ml | 086592 | PKR 258.76 | PKR 2.16/mL | 7% below median |
| Netoplex F.A | Iron polymaltose complex + Folic acid | 100 mg + 350 mcg | Tablet | 3x10's | 086562 | PKR 445.75 | PKR 14.86/tablet | 15% below median |
| NewEscit | Escitalopram | 10 mg | Tablet | 14's | 092985 | PKR 597.90 | PKR 42.71/tablet | 20% below median |
| NewEscit | Escitalopram | 20 mg | Tablet | 14's | 092986 | PKR 768.73 | PKR 54.91/tablet | 9% below median |
| Newflox | Levofloxacin | 750 mg | Tablet | 10's | 086558 | PKR 925.04 | PKR 92.50/tablet | Near median |
| Newflox | Levofloxacin | 500 mg | Tablet | 10's | 086560 | PKR 769.63 | PKR 76.96/tablet | Near median |
| Newflox | Levofloxacin | 250 mg | Tablet | 10's | 086561 | PKR 462.52 | PKR 46.25/tablet | Near median |
| NewIbu | Ibuprofen | 200 mg/5 mL | Suspension | 90ml | 086588 | PKR 111.00 | PKR 1.23/mL | Near median |
| NewIbu | Ibuprofen | 100 mg/5 mL | Suspension | 90ml | 086589 | PKR 61.67 | PKR 0.69/mL | 28% below median |
| NewIbu | Ibuprofen | 100 mg/5 mL | Suspension | 120ml | 086589 | PKR 78.81 | PKR 0.66/mL | 31% below median |
| NewIbu | Ibuprofen | 100 mg/5 mL | Suspension | 60ml | 086589 | PKR 41.12 | PKR 0.69/mL | 28% below median |
| Newlenz | Linezolid | 100 mg/5 mL | Suspension | 60ml | 086587 | PKR 647.53 | PKR 10.79/mL | Near median |
| Newsul | Zinc | 20 mg/5 mL | Syrup | 120ml | 088186 | PKR 222.01 | PKR 1.85/mL | Near median |
| Newsul | Zinc | 20 mg/5 mL | Syrup | 100ml | 088186 | PKR 185.01 | PKR 1.85/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.